# Gerry Maguire

> Gerry Maguire is a Series A investor at Atlantic Bridge (Dublin) backing Semiconductor and GPS. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Atlantic Bridge](https://shizune.co/investors/profile/atlantic-bridge)
- Location: Dublin, Ireland
- Total investments: 12
- Last investment: Jun 2026
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/gerry-maguire/0/b69/903

Gerry Maguire is a Series A investor at Atlantic Bridge in Dublin focused on Semiconductor and GPS. Gerry Maguire is based out of Dublin and is the Co-Founder and General Partner of Atlantic Bridge. Gerry previously worked at Accuris Networks as a Board Member. Gerry Maguire attended the Trinity College Dublin.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Semiconductor | 2 | 17% |
| GPS | 1 | 8% |
| RFID | 1 | 8% |
| Medical | 1 | 8% |
| Big Data | 1 | 8% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 25% |
| Funding Round | 3 | 25% |
| Seed | 2 | 17% |
| Venture - Series Unknown | 2 | 17% |
| Series B | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Ireland | 4 | 33% |
| United States | 2 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ubotica | Ubotica is to deploy advanced Artificial Intelligence technologies on board every satellite. | $11M | Venture - Series Unknown | Jun 23, 2026 |  |
| Neurent Medical | Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $74.5M | Series C | Feb 11, 2026 |  |
| equal1 | Equal1 is accelerating the introduction of useful, cost-effective quantum computers within a three-year time horizon. The company has developed a disruptive, scalable and cost-effective quantum computing technology, based on a commercially available silicon semiconductor process. Our solution uses nanometer-scale quantum dots to form qubits on astandard silicon CMOS process. Along with silicon qubits, we have integrated all functions required for a quantum processing unit (QPU) – the brain of the quantum computer – which operates at 3 kelvin with over 10 million transistors. This is the first integrated quantum processing unit of its kind. | $60M |  | Jan 15, 2026 |  |
| Ubotica | Ubotica is to deploy advanced Artificial Intelligence technologies on board every satellite. | $4.2M | Seed | May 18, 2022 |  |
| equal1 | Equal1 is accelerating the introduction of useful, cost-effective quantum computers within a three-year time horizon. The company has developed a disruptive, scalable and cost-effective quantum computing technology, based on a commercially available silicon semiconductor process. Our solution uses nanometer-scale quantum dots to form qubits on astandard silicon CMOS process. Along with silicon qubits, we have integrated all functions required for a quantum processing unit (QPU) – the brain of the quantum computer – which operates at 3 kelvin with over 10 million transistors. This is the first integrated quantum processing unit of its kind. | $13.2M | Venture - Series Unknown | Dec 20, 2021 |  |
| Neurent Medical | Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $25M | Series B | Jan 20, 2021 |  |
| Neurent Medical | Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $10.2M |  | May 28, 2018 |  |
| Neurent Medical | Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $11M | Series A | May 28, 2018 |  |
| DecaWave | DecaWave is a pioneering fabless semiconductor company which has developed a complete, single chip CMOS ultra wideband IC based on the IEEE802.15.4a standard, and building a family of parts to work at rates 110kbps, 850kbps, 6.8Mbps and 27Mbps.DecaWave has identified the rich potential of ultra wideband (UWB) technology, with particular focuson real time location systems (RTLS) and Wireless Sensor Networks (WSNs), and has been instrumental in developing the alternate PHY IEEE802.15.4a standard.The resulting silicon has a wide range of applications and DecaWave is currently working with lead companies in over 30 different verticals to develop applications in areas as diverse as agriculture, manufacturing, healthcare, lighting, security, transport, inventory & supply chain management. | $31.8M |  | Feb 21, 2018 |  |
| Siren | Siren is a software company that provides an Investigative Intelligence platform to complex organizations and derive business value. The platform provides a unique combination of search, business intelligence, big data, link analysis and knowledge representation which advances the way organizations address some of the world’s most importantdata-driven problems.Siren makes it easier to use the data you collect to answer questions and make links, find patterns and relationships. It also uniquely enables this in real-time at a scale that companies and government organizations require. it easy to leverages and deploy data directly on backends such as Elasticsearch, relational databases, virtual data warehouses, and graph databases.Siren was awarded the Technology Innovation of the Year and Enterprise of the Year (SME) at the Information Technology Association of Galway (ITAG) Excellence Awards and also was named the Irish Startup of the Year at Ireland’s National Tech Excellence Awards.Siren was founded in 2014 and is based in Galyway, Ireland. | $3.3M | Series A | Feb 07, 2018 |  |

10 of 12 investments shown.

## Co-investors
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 5 deals together
- [Fountain Healthcare Partners](https://shizune.co/investors/profile/fountain-healthcare-partners) — VC Fund, 4 deals together
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund, 2 deals together
- [Frontline Ventures](https://shizune.co/investors/profile/frontline-ventures) — VC Fund, 2 deals together
- [Life Sciences Fund Amsterdam](https://shizune.co/investors/profile/life-sciences-fund-amsterdam) — VC Fund, 2 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together

## About Atlantic Bridge

VC Fund · Dublin, Ireland

Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up andexploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies.Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.

5 contacts available at Atlantic Bridge.

| Name | Title | Profile |
| --- | --- | --- |
| Brian Long | Managing Partner | https://shizune.co/investors/profile/brian-long-4 |
| Gerry Maguire | Co-Founder and General Partner | https://shizune.co/investors/profile/gerry-maguire |
| Helen McBreen | Partner | https://shizune.co/investors/profile/helen-mcbreen |
| Kevin Dillon | Managing Partner & Co-Founder | https://shizune.co/investors/profile/kevin-dillon |
| Chris Horn | Venture Partner | https://shizune.co/investors/profile/chris-horn |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gerry Maguire invest in?

Gerry Maguire invests primarily in Semiconductor, GPS and RFID startups, most often at Series A and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gerry Maguire last invest?

The most recent investment recorded for Gerry Maguire closed in Jun 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co